US Patent

US8415395 — Colchicine compositions and methods

Method of Use · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2028-10-06 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating gout flares with colchicine compositions.

USPTO Abstract

Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.

Drugs covered by this patent

Colcrys (COLCHICINE) · Scilex Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1007`	—	Colcrys

Patent Metadata

Patent number: US8415395
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceuticals USA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.